BeiGene | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

⟵ Back to Search Results

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Beigene Study ID

BGB-900-105

ClinicalTrials.gov ID

NCT04047862

China Drug Trials ID

CTR20202608

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents